Cantor Fitzgerald Predicts TARA FY2025 Earnings

Protara Therapeutics, Inc. (NASDAQ:TARA) – Analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Protara Therapeutics in a research report issued to clients and investors on Monday, March 17th. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings of ($1.62) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Protara Therapeutics’ current full-year earnings is ($3.32) per share.

TARA has been the topic of a number of other reports. HC Wainwright reiterated a “buy” rating and set a $23.00 price target on shares of Protara Therapeutics in a research note on Thursday, March 6th. Guggenheim reiterated a “buy” rating and set a $20.00 price target on shares of Protara Therapeutics in a research note on Friday, December 6th. Finally, Lifesci Capital began coverage on shares of Protara Therapeutics in a research note on Tuesday, March 11th. They set an “outperform” rating and a $22.00 price target on the stock. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $22.50.

Protara Therapeutics Price Performance

Shares of NASDAQ:TARA opened at $4.71 on Wednesday. The firm has a market capitalization of $97.17 million, a PE ratio of -1.67 and a beta of 1.69. The firm’s 50-day moving average is $4.33 and its two-hundred day moving average is $3.53. Protara Therapeutics has a 1 year low of $1.60 and a 1 year high of $10.48.

Protara Therapeutics (NASDAQ:TARA) last issued its quarterly earnings results on Wednesday, March 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.09.

Hedge Funds Weigh In On Protara Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. RA Capital Management L.P. grew its position in shares of Protara Therapeutics by 78.9% during the fourth quarter. RA Capital Management L.P. now owns 3,400,000 shares of the company’s stock worth $17,952,000 after buying an additional 1,500,000 shares in the last quarter. Janus Henderson Group PLC acquired a new position in shares of Protara Therapeutics during the fourth quarter worth about $11,938,000. Adage Capital Partners GP L.L.C. acquired a new position in shares of Protara Therapeutics during the fourth quarter worth about $11,880,000. Toronto Dominion Bank acquired a new position in shares of Protara Therapeutics during the fourth quarter worth about $11,030,000. Finally, Blackstone Inc. acquired a new position in shares of Protara Therapeutics during the fourth quarter worth about $8,870,000. 38.13% of the stock is owned by institutional investors and hedge funds.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.